Physician profile
Sarah N Devaro
NPI 1205322419
$4,465.33
in general payments reported to CMS, 2019-2025
21 companies · $948 in 2025
The $948 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $508 · 2023: $1,002 · 2024: $2,008 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,957.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,202.20 | 2022-2025 | Clareon, Hydrus Microstent, Unity |
| Abbvie INC. | $812.92 | 2022-2025 | Xen Glaucoma Treatment System |
| Glaukos Corporation | $628.12 | 2022-2025 | Idose, Idosetr |
| Bausch & Lomb Americas INC. | $351.37 | 2022-2024 | Ic-8 Apthera Iol, Envista Mx60 Iol |
| Tarsus Pharmaceuticals, INC. | $152.47 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $128.87 | 2024-2025 | Tecnis Simplicity, Catalys System, Tecnis Iol |
| Dompe US, INC. | $122.66 | 2025 | Oxervate |
| Harrow Eye, LLC | $121.80 | 2024 | Verkazia, Iheezo, Flarex |
| Axogen | $121.30 | 2023 | Avance Nerve Graft |
| Sun Pharmaceutical Industries INC. | $119.21 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $114.15 | 2024 | Eylea Hd |
| Rxsight INC | $112.71 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Astellas Pharma US INC | $98.68 | 2024 | Izervay |
| Carl Zeiss Meditec USA, INC. | $96.40 | 2023 | Forum |
| New World Medical,INC. | $96.06 | 2025 | Clearpath, Ahmed Glaucoma Valve, Via360 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73.11 | 2022 | |
| Amgen INC. | $27.95 | 2025 | Tepezza |
| Thea Pharma INC. | $22.85 | 2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $22.83 | 2025 | Dextenza |
| Biotissue Holdings INC. | $22.50 | 2025 | |
| Rayner Intraocular Lenses Limited | $17.17 | 2024 | Rayone Aspheric, Rayone Emv, Rayner Cataract Set 1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Devaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.